TCR-engineered T cell therapy in solid tumors: State of the art and perspectives - CNRS - Centre national de la recherche scientifique Access content directly
Journal Articles Science Advances Year : 2023

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

Nicolas Chuvin

Abstract

T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell malignancies in hematology. However, their clinical impact on solid tumors has been modest so far. T cells expressing an engineered T cell receptor (TCR-T cells) represent a promising therapeutic alternative. The target repertoire is not limited to membrane proteins, and intrinsic features of TCRs such as high antigen sensitivity and near-to-physiological signaling may improve tumor cell detection and killing while improving T cell persistence. In this review, we present the clinical results obtained with TCR-T cells targeting different tumor antigen families. We detail the different methods that have been developed to identify and optimize a TCR candidate. We also discuss the challenges of TCR-T cell therapies, including toxicity assessment and resistance mechanisms. Last, we share some perspectives and highlight future directions in the field.

Domains

Cancer
Fichier principal
Vignette du fichier
sciadv.adf3700.pdf (1.73 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04115921 , version 1 (28-02-2024)

Identifiers

Cite

Estelle Baulu, Célia Gardet, Nicolas Chuvin, Stéphane Depil. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Science Advances , 2023, 9 (7), ⟨10.1126/sciadv.adf3700⟩. ⟨hal-04115921⟩
29 View
6 Download

Altmetric

Share

Gmail Facebook X LinkedIn More